Article Text

Download PDFPDF
948 EQ-5D utility scores for risk-reducing mastectomy and risk-reducing salpingo-oophorectomy: mapping from SF-12 and SF-36
  1. Samuel Oxley1,
  2. Xia Wei1,
  3. Michail Sideris1,
  4. Oleg Blyuss1,
  5. Ashwin Kalra1,
  6. Jacqueline Sia1,
  7. Subhasheenee Ganesan1,
  8. Caitlin T Fierheller1,
  9. Li Sun2,
  10. Zia Sadique2,
  11. Haomiao Jin3,
  12. Ranjit Manchanda4 and
  13. Rosa Legood2
  1. 1Queen Mary University of London, London, UK
  2. 2London School of Hygiene and Tropical Medicine, London, UK
  3. 3University of Surrey, Surrey, UK
  4. 4Barts and the Royal London Hospital, London, UK


Introduction/Background It is essential to understand quality-of-life after risk-reducing surgery to counsel patients and inform health-economic analysis. The measure preferred by NICE and other guideline committees is EQ-5D, used to generate health-related utility scores, which rank quality-of-life from 0 (death) to 1 (full health). No previous study has reported EQ-5D utility scores for risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) for breast and ovarian cancer prevention, sourced directly from patients. The aim of this study is to obtain and summarise the best available evidence of EQ-5D utility scores for RRM and RRSO, mapping from other quality-of-life measures.

Methodology We used aggregate data from our previously published systematic review of the literature (PMID 37059410). We converted PCS-12/36 and MCS-12/36 to EQ-5D utility scores using a published mapping algorithm. The study control arm or age-matched country-specific reference values were used for comparison. Random-effects meta-analysis provided adjusted disutilities and utility scores for RRM and RRSO. Subgroup analyses included RRM under vs over 2 years’ follow-up, RRSO under vs over 1 year follow-up, and RRSO in pre- vs post-menopausal women.

Results Four studies (209 patients) reported RRM outcomes using SF-36, five studies (742 patients) reported RRSO outcomes using SF-12/SF-36. RRM is associated with a long-term adjusted disutility of -0.08 (95% CI -0.11, -0.04)(I2 31.4%), and an adjusted utility score of 0.92 (95% CI 0.88, 0.95)(I2 31.4%). RRSO is associated with a long-term adjusted disutility of -0.03 (95% CI -0.05, 0.00)(I2 17.2%) and an adjusted utility score of 0.97 (95% CI 0.94, 0.99)(I2 34.0%).

Conclusion We present the only available EQ-5D utility scores in the literature sourced from patients who have undergone RRM and RRSO. These are highly relevant for counselling patients and for international researchers conducting health-economic analyses of breast and ovarian cancer prevention.

Disclosures No relevant disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.